MX2023006786A - Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control. - Google Patents
Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.Info
- Publication number
- MX2023006786A MX2023006786A MX2023006786A MX2023006786A MX2023006786A MX 2023006786 A MX2023006786 A MX 2023006786A MX 2023006786 A MX2023006786 A MX 2023006786A MX 2023006786 A MX2023006786 A MX 2023006786A MX 2023006786 A MX2023006786 A MX 2023006786A
- Authority
- MX
- Mexico
- Prior art keywords
- immunomodulatory antibodies
- checkpoint receptors
- bind costimulatory
- bispecific immunomodulatory
- bispecific
- Prior art date
Links
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 2
- 108091008028 Immune checkpoint receptors Proteins 0.000 title 1
- 102000037978 Immune checkpoint receptors Human genes 0.000 title 1
- 230000000139 costimulatory effect Effects 0.000 title 1
- 108091008034 costimulatory receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381239P | 2016-08-30 | 2016-08-30 | |
| US201762456033P | 2017-02-07 | 2017-02-07 | |
| US201762479723P | 2017-03-31 | 2017-03-31 | |
| US15/623,314 US10787518B2 (en) | 2016-06-14 | 2017-06-14 | Bispecific checkpoint inhibitor antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006786A true MX2023006786A (es) | 2023-06-20 |
Family
ID=65632988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006786A MX2023006786A (es) | 2016-08-30 | 2019-02-27 | Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3507306B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7080219B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102575681B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110267990B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017321625A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3035343A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3507306T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20251424T1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL265046B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006786A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201901712YA (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201901752B (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3044323B1 (en) * | 2013-09-13 | 2022-04-06 | F. Hoffmann-La Roche AG | Methods for detecting and quantifying host cell protein in cell lines |
| KR102170077B1 (ko) * | 2018-05-21 | 2020-10-27 | 인하대학교 산학협력단 | Prss14/st14의 자가분해 고리부분을 특이적으로 인식하는 단일클론항체 및 이의 용도 |
| CN112996813A (zh) * | 2018-10-31 | 2021-06-18 | 生物蛋白有限公司 | 抗ctla4抗体、抗体片段、其免疫结合物和其用途 |
| AU2021257570A1 (en) * | 2020-04-14 | 2022-11-03 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| JP2023521228A (ja) * | 2020-04-14 | 2023-05-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 癌の併用療法 |
| CN116615442A (zh) * | 2020-09-08 | 2023-08-18 | 优特力克斯有限公司 | 程序性细胞死亡1多肽变体 |
| CN114195900B (zh) * | 2020-09-17 | 2024-02-23 | 普米斯生物技术(珠海)有限公司 | 一种抗4-1bb/pd-l1双特异性抗体及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8546543B2 (en) * | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| TWI605828B (zh) * | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| WO2012065055A2 (en) * | 2010-11-12 | 2012-05-18 | The Rockefeller University | Fusion proteins for hiv therapy |
| UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CA3211863A1 (en) * | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Novel heterodimeric proteins |
| EP2951203B1 (en) * | 2013-03-15 | 2019-05-22 | Xencor, Inc. | Heterodimeric proteins |
| US10544187B2 (en) * | 2013-03-15 | 2020-01-28 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| EP3024851B1 (en) * | 2013-07-25 | 2018-05-09 | CytomX Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| NZ720353A (en) * | 2013-12-30 | 2019-12-20 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
| EA201790834A1 (ru) * | 2014-10-14 | 2018-01-31 | Новартис Аг | Молекулы антител к pd-l1 и их применение |
| EA038349B1 (ru) * | 2014-11-21 | 2021-08-12 | Бристол-Маерс Сквибб Компани | Антитела, содержащие модифицированные константные участки тяжелой цепи |
| SG11201704274QA (en) * | 2014-11-26 | 2017-06-29 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38 |
| PT3242890T (pt) * | 2015-01-08 | 2019-12-10 | Genmab As | Agentes de ligação agonistas do recetor de tnf |
| EP3245227A4 (en) * | 2015-01-14 | 2018-07-25 | Compass Therapeutics LLC | Multispecific immunomodulatory antigen-binding constructs |
| MA41414A (fr) * | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
-
2017
- 2017-08-30 CN CN201780060900.7A patent/CN110267990B/zh active Active
- 2017-08-30 IL IL265046A patent/IL265046B2/en unknown
- 2017-08-30 AU AU2017321625A patent/AU2017321625A1/en not_active Abandoned
- 2017-08-30 HR HRP20251424TT patent/HRP20251424T1/hr unknown
- 2017-08-30 KR KR1020197009280A patent/KR102575681B1/ko active Active
- 2017-08-30 SG SG11201901712YA patent/SG11201901712YA/en unknown
- 2017-08-30 JP JP2019511464A patent/JP7080219B2/ja active Active
- 2017-08-30 KR KR1020237029969A patent/KR20230130174A/ko not_active Ceased
- 2017-08-30 CA CA3035343A patent/CA3035343A1/en active Pending
- 2017-08-30 EP EP17765002.5A patent/EP3507306B1/en active Active
- 2017-08-30 DK DK17765002.5T patent/DK3507306T3/da active
-
2019
- 2019-02-27 MX MX2023006786A patent/MX2023006786A/es unknown
- 2019-03-20 ZA ZA2019/01752A patent/ZA201901752B/en unknown
-
2022
- 2022-05-24 JP JP2022084854A patent/JP2022111148A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7080219B2 (ja) | 2022-06-03 |
| CN110267990A (zh) | 2019-09-20 |
| JP2019529368A (ja) | 2019-10-17 |
| JP2022111148A (ja) | 2022-07-29 |
| CA3035343A1 (en) | 2018-03-08 |
| HRP20251424T1 (hr) | 2025-12-19 |
| AU2017321625A1 (en) | 2019-04-04 |
| IL265046B1 (en) | 2024-12-01 |
| KR102575681B1 (ko) | 2023-09-08 |
| CN110267990B (zh) | 2023-11-07 |
| RU2019109147A3 (cg-RX-API-DMAC7.html) | 2021-01-22 |
| KR20230130174A (ko) | 2023-09-11 |
| EP3507306A1 (en) | 2019-07-10 |
| KR20190044106A (ko) | 2019-04-29 |
| RU2019109147A (ru) | 2020-10-05 |
| DK3507306T3 (da) | 2025-10-20 |
| ZA201901752B (en) | 2020-09-30 |
| IL265046B2 (en) | 2025-04-01 |
| IL265046A (en) | 2019-04-30 |
| SG11201901712YA (en) | 2019-03-28 |
| EP3507306B1 (en) | 2025-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124993T1 (el) | Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20 | |
| AU2018366199A1 (en) | Bispecific and monospecific antibodies using novel anti-PD-1 sequences | |
| CY1123236T1 (el) | Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3 | |
| PH12017500982A1 (en) | Heterodimeric antibodies that bind cd3 and cd38 | |
| MX2023006786A (es) | Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control. | |
| PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
| PH12017502019B1 (en) | Heterodimeric antibodies that bind cd3 and tumor antigens | |
| MX2017007491A (es) | Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso. | |
| EP4257613A3 (en) | Bispecific checkpoint inhibitor antibodies | |
| MX2020009649A (es) | Anticuerpos monoclonales contra bcma. | |
| SG10201901057UA (en) | Anti-pd-l1 antibodies | |
| CL2018000729A1 (es) | Anticuerpos biespecíficos contra el a-beta humano y el receptor de transferrina humano y métodos de uso. | |
| MX2015013901A (es) | Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos. | |
| MX2015017331A (es) | Anticuerpos anti fc similar a receptor 5 (fcrh5). | |
| PH12016501894A1 (en) | Anti-ox40 antibodies and methods of use | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| PE20210648A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
| MX2018008369A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
| EP3705494A3 (en) | Antibodies against frizzled proteins and methods of use thereof | |
| ZA201800804B (en) | Novel anti-human gpvi antibodies and uses thereof | |
| PH12019501605A1 (en) | Glucagon receptor binding proteins and methods of use thereof | |
| MX2018009218A (es) | Anticuerpos de cgrp y sus usos. | |
| MX2019002349A (es) | Anticuerpos inmunomoduladores biespecíficos que se fijan a receptores coestimuladores y de puntos de control. |